Advertisement

Reply to Editorial Comment

      The UKCCCR trial of the frequency of breast cancer screening is published in this issue and is accompanied by a commentary from Dr Ingvar Andersson.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Blamey R.W.
        The design and clinical use of the Nottingham Prognostic Index in breast cancer.
        The Breast. 1996; 5: 156-157
        • Balslev I.
        • Axelsson C.K.
        • Zedelar K.
        • Rasmussen B.B.
        • Cartensen B.
        • Mouridsen H.T.
        The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG).
        Breast Cancer Res & Treat. 1994; 32: 281-290
        • Sundquist M.
        • Thorstenson S.
        • Brudin L.
        • Wingren S.
        • Nordenskjold B.
        Incidence and prognosis in early onset breast cancer.
        The Breast. 2002; 11: 30-35
        • D'Eredita G.
        • Martellotta M.
        • Natale T.
        • Ferrarese F.
        Prognostic factors in breast cancer.
        Eur. J. Cancer. 2001; 37: 591-596